Drug Interaction Issues

• PK Enhancers:

  • No information in labels re: PK enhancer (e.g. subtherapeutic doses of ritonavir) + PI
  • Preliminary data on certain interactions show increase in AUC and Cmin and decrease in Cmax

4. Which exposure measures should be considered when providing labeling information on concomitant administration of antiretrovirals?

Previous slide

Next slide

Back to first slide

View graphic version